Cardiology - European Medical Journal

Continue

Cardiology

Filter
9 Mins
17 Oct 2019

A Review of the Burden of Atrial Fibrillation: Understanding the Impact of the New Millennium Epidemic across Europe

Atrial fibrillation (AF), the most common form of arrhythmia, is characterised by an irregular and often fast heart rhythm resulting in uncoordinated…
9 Mins
17 Oct 2019

Tricuspid Regurgitation: No Longer the ‘Forgotten’ Valve

In the last two decades, the interest in tricuspid valve (TV) treatment has increased;1,2 nevertheless, there is still a large percentage…
11 Mins
17 Oct 2019

Chemokines: A Potential Therapeutic Target for the Stabilisation of Vulnerable Plaque

In the late 20th century, lipid lowering medications appeared to be the answer for coronary heart disease. However, despite reductions in mortality…
9 Mins
17 Oct 2019

Circulating Cardiac Biomarkers in Heart Failure: A Critical Link to Biomarker-Guided Therapy

A contemporary conceptual framework that was proposed to distinguish between different chronic heart failure (HF) patients has highlighted varying…
10 Mins
6 Sep 2019

A Clinical Review of Ventricular Arrhythmias in Patients with Congestive Heart Failure

Pump failure and sudden cardiac death are the leading causes of death in heart failure patients; sudden cardiac death accounts for 30–50% of deaths…
9 Mins
14 Mar 2019

Inflammation and Thrombosis in Coronary Atherosclerosis: Pathophysiologic Mechanisms and Clinical Correlations

The importance of inflammation and thrombosis in the pathophysiology of atherosclerosis was debated in the 19th century by two prominent pathologists…
10 Mins
11 Oct 2018

Guidelines, Clinical Evidence, and Real-Life Practice: How to Find Your Way in Managing Hypercholesterolaemia

Prof Masana presented evidence that low-density lipoprotein (LDL) cholesterol is a causal factor for atherosclerosis and that cardiovascular disease (CVD…
4 Mins
11 Oct 2018

Reversal of Apixaban and Rivaroxaban Anticoagulation by Andexanet Alfa in ANNEXA-A and ANNEXA-R as Assessed by Non-Tissue Factor-Initiated Thrombin Generation Independent of Tissue Factor Pathway Inhibitor

Andexanet alfa is a modified factor Xa (FXa) drug designed to bind and sequester FXa inhibitors and thus reverse anticoagulation…